← Back to Search

Artificial Intelligence

Evaluation of CAD-EYE/SCALE-EYE for Detection, Classification, and Measurement of Colorectal Polyps: a Prospective Study

N/A
Waitlist Available
Led By Daniel von Renteln
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, estimation: 3 months
Awards & highlights
No Placebo-Only Group

Summary

This trial uses AI systems CAD-eye and SCALE-EYE to help doctors find and measure polyps during colonoscopies in adults aged 45 to 80. CAD-eye detects and classifies polyps, while SCALE-EYE measures their size accurately.

Eligible Conditions
  • Colorectal Adenomas

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, estimation: 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, estimation: 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Evaluation of CADe function
Evaluation of the Scale-Eye
Secondary study objectives
3D scanning assessment
Agreement and discrepancy between SCALE-EYE and other measurement
CADe function: proportion of polyps detected
+6 more
Other study objectives
A pilot feasibility study using the first 40 recruited patients for determining the best reference for evaluating the SCALE-EYE performance

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Artificial intelligence for real-time detection and monitoring of colorectal polypsExperimental Treatment1 Intervention
Colonoscopies will be performed according to the standard of care. Patients will undergo colonoscopies using CAD-eye (CADe and CADx) and Scale-eye. All optically diagnosed (CADx) polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards. CADx will be combined with human input for final diagnosis.
Group II: Real time polyp detection using a standard colonoscopy without CAD eyeActive Control1 Intervention
Real time polyp detection using a standard colonoscopy without CAD eye and without CADe. Patients will undergo a standard colonoscopy. Polyp size measurement will be assessed visually (phase 1 and 2) or with instruments such as snare or forceps (phase 3 or later) and polyp classification will be done by CADx without further input by the endoscopist. All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Detection and classification and size measurement of polyp by Artificial Intelligence (Cad eye) and the Scale Eye
2022
N/A
~350

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
377 Previous Clinical Trials
131,172 Total Patients Enrolled
1 Trials studying Colorectal Adenomas
540 Patients Enrolled for Colorectal Adenomas
Daniel von RentelnPrincipal InvestigatorCentre hospitalier de l'Université de Montréal (CHUM)
5 Previous Clinical Trials
1,470 Total Patients Enrolled

Media Library

CAD-EYE/SCALE-EYE (Artificial Intelligence) Clinical Trial Eligibility Overview. Trial Name: NCT05236790 — N/A
Colorectal Adenomas Research Study Groups: Artificial intelligence for real-time detection and monitoring of colorectal polyps, Real time polyp detection using a standard colonoscopy without CAD eye
Colorectal Adenomas Clinical Trial 2023: CAD-EYE/SCALE-EYE Highlights & Side Effects. Trial Name: NCT05236790 — N/A
CAD-EYE/SCALE-EYE (Artificial Intelligence) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05236790 — N/A
~99 spots leftby Dec 2025